Melanoma-derived factors alter the maturation and activation of differentiated tissue-resident dendritic cells

Immunology and Cell Biology

Volumn 94, Issue 1, 2016, Pages 24-38

  Hargadon, Kristian M ^a   Bishop, Johnathan D ^a   Brandt, John P ^a   Hand, Zachary C ^a   Ararso, Yonathan T ^a   Forrest, Osric A ^a  

^a HAMPDEN SYDNEY COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; VASCULOTROPIN C; CHEMOKINE; IMMUNOLOGIC FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL ISOLATION; CELL MATURATION; CELL POPULATION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ASSOCIATION; EX VIVO STUDY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; SPLEEN; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; C57BL MOUSE; CD8+ T LYMPHOCYTE; CELL COUNT; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IMMUNOLOGY; LUNG; LYMPHOCYTE ACTIVATION; MACROPHAGE; METABOLISM; PATHOLOGY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; CELL DIFFERENTIATION; CHEMOKINES; DENDRITIC CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; IMMUNOLOGIC FACTORS; LUNG; LYMPHOCYTE ACTIVATION; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; SPLEEN; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84983096371     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2015.58     Document Type: Article

References (59)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
2. Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001; 2: 1010-1017.
3. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194: 769-780.
4. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233-238.
5. Probst HC, Lagnel J, Kollias G, Van den Broek M. Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity 2003; 18: 713-720.
6. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
7. Janeway CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
8. Reis e Sousa C. Activation of dendritic cells: translating innate into adaptive immunity. Curr Opin Immunol 2004; 16: 21-25.
9. Nguyen LT, Elford AR, Murakami K, Garza KM, Schoenberger SP, Odermatt B et al. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med 2002; 195: 423-435.
10. Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M et al. Type I IFNs control antigen retention and survival of CD8?(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol 2011; 186: 5142-5150.
11. Hermans IF, Daish A, Yang J, Ritchie DS, Ronchese F. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumorspecific cytotoxic T lymphocyte precursors. Cancer Res 1998; 58: 3909-3917.
12. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 1999; 96: 2233-2238.
13. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emph Tumor Immunol 1996; 19: 81-84.
14. Yamshchikov G, Thompson L, Ross WG, Galavotti H, Aguila W, Deacon D et al. Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations. Clin Cancer Res 2001; 7: 909s-916s.
15. Anichini A, Scarito A, Molla A, Parmiani G, Mortarini R. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines. J Immunol 2003; 171: 2134-2141.
16. Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-Antigens in human metastatic melanoma. Cancer Res 2003; 63: 2535-2545.
17. Zippelius A, Batard P, Rubio-Godov V, Bioley G, Lienard D, Lejeune F et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance. Cancer Res 2004; 64: 2865-2873.
18. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS et al. Characterization of circulating T cells specific for tumor-Associated antigens in melanoma patients. Nat Med 1999; 5: 677-685.
19. Hargadon KM, Brinkman CC, Sheasley-O'neill SL, Nichols LA, Bullock TN, Engelhard VH. Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes. J Immunol 2006; 177: 6081-6090.
20. Hargadon KM. Tumor-Altered dendritic cell function: implications for anti-tumor immunity. Front Immunol 2013; 4: 192.
21. Hargadon KM. Melanoma immunotherapy: overcoming obstacles to augment anti-tumor immune responses. Journal of Cosmetics, Dermatological Sciences and Applications 2013; 3: 7-27.
22. Hargadon KM, Ararso YT, Forrest OA, Harte CM. Melanoma-Associated suppression of the dendritic cell lines DC2.4 and JAWSII. Am J Immunol 2012; 8: 179-190.
23. Hargadon KM, Forrest OA, Reddy PR. Suppression of the maturation and activation of the dendritic cell line DC2.4 by melanoma-derived factors. Cell Immunol 2012; 272: 275-282.
24. Knisely TL, Niederkorn JY. Immunologic evaluation of spontaneous regression of an intraocular murine melanoma. Invest Ophthalmol Vis Sci 1990; 31: 247-257.
25. Quatromoni JG, Eruslanov E. Tumor-Associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res 2012; 4: 376-389.
26. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678-689.
27. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66: 1123-1131.
28. Xiang X, Poliakov A, Lie C, Lie Y, Deng ZB, Wang J et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 2009; 124: 2621-2633.
29. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998; 92: 4778-4791.
30. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-4506.
31. Sombroek CC, Stam AG, Masterson AJ, Lougheed SM, Schakel MJ, Meijer CJ et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol 2002; 168: 4333-4343.
32. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003; 198: 1741-1752.
33. Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F et al. Significance of M2-polarized tumor-Associated macrophage in pancreatic cancer. J Surg Res 2011; 167: e211-e219.
34. Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998; 28: 359-369.
35. ONeill HC, Wilson HL. Limitations with in vitro production of dendritic cells using cytokines. J Leukoc Biol 2004; 75: 600-603.
36. Alshamsan A, Hamdy S, Das S, Lavasanifar A, Samuel J, El-Kadi AO. Validation of bone marrow derived dendritic cells as an appropriate model to study tumor-mediated suppression of DC maturation through STAT3 hyperactivation. J Pharm Pharm Sci 2010; 13: 21-26.
37. Idoyaga J, Moreno J, Bonifaz L. Tumor cells prevent mouse dendritic cell maturation induced by TLR ligands. Cancer Immunol Immunother 2007; 56: 1237-1250.
38. Marton A, Vizler C, Kusz E, Temesfoi V, Szathmary Z, Nagy K et al. Melanoma cellderived exosomes alter macrophage and dendritic cell functions in vitro. Immunol Lett 2012; 148: 34-38.
39. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92: 4150-4166.
40. Yamaguchi Y, Tsumura H, Miwa M, Inaba K. Contrasting effects of TGF-beta 1 and TNF-Alpha on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 1997; 15: 144-153.
41. Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012; 209: 495-506.
42. Krempski J, Karyampudi L, Behrens MD, Erskine CL, Hartmann L, Dong H et al. Tumorinfiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol 2011; 186: 6905-6913.
43. Michielsen AJ, Hogan AE, Marry J, Tosetto M, Cox F, Hyland JM et al. Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. PLoS ONE 2011; 6: e27944.
44. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114: 280-290.
45. von Bergwelt-Baildon MS, Popov A, Saric T, Chemnitz J, Classen S, Stoffel MS et al. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-Associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 2006; 108: 228-237.
46. Ferguson AR, Nichols LA, Zarling AL, Thompson ED, Brinkman CC, Hargadon KM et al. Strategies and challenges in eliciting immunity to melanoma. Immunol Rev 2008; 222: 28-42.
47. Musha H, Ohtani H, Mizoi T, Kinouchi M, Nakayama T, Shiiba K et al. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer 2005; 116: 949-956.
48. Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 2008; 68: 8437-8445.
49. Lavergne E, Combadiere C, Iga M, Boissonnas A, Bonduelle O, Maho M et al. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J Immunol 2004; 173: 3755-3762.
50. Godiska R, Chantry D, Raport CJ, Sozzani S, Allavena P, Leviten D et al. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J Exp Med 1997; 185: 1595-1604.
51. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995; 182: 155-162.
52. Wan S, Pestka S, Jubin RG, Lyu YL, Tsai YC, Lie LF. Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PloS One 2012; 7: e32542.
53. Chen L, Mory Y, Zilberstein A, Revel M. Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2. Proc Natl Acad Sci USA 1988; 85: 8037-8041.
54. Taylor KL, Leaman DW, Grane R, Mechti N, Borden EC, Lindner DJ. Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro. J Interferon Cytokine Res 2008; 28: 733-740.
55. Owen JD, Strieter R, Burdick M, Haghnegahdar H, Nanney L, Shattuck-Brandt R et al. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins. Int J Cancer 1997; 73: 94-103.
56. Haghnegahdar H, Du J, Wang D, Strieter RM, Burdick MD, Nanney LB et al. The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J Leukoc Biol 2000; 67: 53-62.
57. Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol 2002; 72: 9-18.
58. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008; 99: 1501-1506.
59. Hao X, Kim TS, Braciale TJ. Differential response of respiratory dendritic cell subsets to influenza virus infection. J Virol 2008; 82: 4908-4919.